Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

BioCare's Ryan Cort outlines the pharmaceutical industry's "unprecedented sea change," driven by over $400 billion in anticipated revenue loss from generics and biosimilars losing exclusivity. 

Trade & Channel Strategies 2025: The $405 Billion Patent Cliff Demands Partnership and Adaptive Market Access Strategies

Podcasts

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

Pharma Pulse: ACA Subsidy Gridlock Spurs Cost Crisis, as Lilly’s Retatrutide Delivers Positive Results in Phase III Trial

In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.

Pharma Pulse: FDA Shifts CAR-T Standards and Maryland Expands Medical Class Size, as Pharma Channels Brace for Massive Patent Cliff Disruption

Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.

Trade & Channel Strategies 2025: How Regulatory & Patent Cliff Disruption is Remaking Pharma Channels

In today’s Pharma Pulse, new trials confirm AI chatbots are a successful and sustainable tool for increasing pneumococcal vaccine uptake among older adults and much more.

Pharma Pulse: Lilly’s Jaypirca Challenges Imbruvica, as AI Chatbots Could Prove Key to Boosting Vaccine Rates

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

In today’s Pharma Pulse, a structured exercise program is proven to manage persistent long COVID symptoms, while Regeneron commits $150 million upfront to Tessera for a gene writing therapy targeting AATD, and Strive Pharmacy invests in a massive Arizona facility to boost national personalized medicine capacity.

Pharma Pulse: Long COVID Exercise Win, $150M Gene Editing Play, and Compounding Pharmacy Expansions

The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a significant change to the UK's NICE value appraisal framework. 

US and UK Agree to Zero Tariffs on Pharmaceuticals 

The Trump administration has announced new negotiated Medicare prices for a second wave of blockbuster treatments, yielding an estimated $12 billion in savings for 2027, when compared to Medicare’s 2024 net spending.

It’s Official: CMS Unveils Big Price Cuts for 15 High-Cost Medicare Drugs in Latest IRA Negotiation Round

As the federal government prepares to release newly negotiated Medicare drug prices, weight-loss blockbusters Ozempic and Wegovy remain in the spotlight, while CMS advances a model to cut Medicaid spending and broaden access to affordable treatments.

Business and Finance